Sab Biotherapeutics Inc. Class WSABSWPreferred / convertible
13F holders, Q4 2024 (December 31)9holders
2new positions
2sold out
$0.08avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Sab Biotherapeutics Inc. Class W (SABSW) in their 13F filings, unchanged from Q3 2024. 2 opened new positions and 2 sold out. The largest holders were LMR Partners LLP ($41K), Morgan Stanley ($11K) and Yakira Capital Management, Inc. ($7K).
- Company
- Sab Biotherapeutics Inc. Class W
- CUSIP
- 78397T111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $41K |
| Exits | 2 | $844 |
All 13F filers, Q3 2024 → Q4 2024: 564,479 shares bought and 305,576 shares sold, net +258,903 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| LMR Partners LLP | — | New | 539,588 | $41K |
| Morgan Stanley | — | No change | 146,439 | $11K |
| Yakira Capital Management, Inc. | — | Reduce -14.1% | 93,230 | $7K |
| HB Wealth Management, LLC | — | Reduce -83.9% | 50,001 | $4K |
| Walleye Trading LLC | — | Add +150.0% | 38,763 | $3K |
| Wolverine Asset Management LLC | — | Reduce -44.2% | 8,655 | $651 |
| UBS Group AG | — | New | 1,633 | $122 |
| NewEdge Advisors, LLC | — | No change | 1,072 | $80 |
| Tower Research Capital LLC (TRC) | — | No change | 48 | $4 |
"% of holder's portfolio" is SABSW's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. Class W the manager owns.